No serious side effects or discomfort observed Final safety and absorption data expected in March 2025 SARASOTA, FL, Feb. 11, ...

Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, ...

Veloxity Labs, a bioanalytical contract research organization (CRO) specializing in accelerating therapeutic development, is proud to announce a partnership with Aplos Analytics. This collaboration ...

Optimising the dosing of medicines for neonates and children remains a challenge. The importance of pharmacokinetic (PK) and pharmacodynamic (PD) research is recognised both in medicines regulation ...

Dr. Novelli, together with her co-authors, presented "Intra-arterial Gemcitabine Versus Intravenous Gemcitabine: Pharmacokinetic Sub-study of the TIGeR-PaC Phase 3 Clinical Trial," a sub-study of ...

The primary endpoint was to evaluate the safety, tolerability, and pharmacokinetic (PK) profiles of a subcutaneous injection of AK111, and the secondary endpoint was to evaluate its clinical efficacy ...

Dr. Novelli, together with her co-authors, presented “Intra-arterial Gemcitabine Versus Intravenous Gemcitabine: Pharmacokinetic Sub-study of the TIGeR-PaC Phase 3 Clinical Trial,” a sub-study ...

No serious side effects or discomfort observed Final safety and absorption data expected in March 2025 SARASOTA, FL, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) ("Silo" or the ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

Chen et al. established a population pharmacokinetic (PPK) model for isoniazid (INH) and its major metabolite acetylisoniazid (AcINH) in healthy Chinese participants and tuberculosis patients and ...

Enrolment in this trial is expected to continue through the first quarter of 2025. Satellos is on track to submit a Phase II ...